Related Experiment Video
Updated: Mar 22, 2026
07:03
Author Spotlight: Integrating Computational and Experimental Approaches in Precision Oncology
Published on: December 1, 2023
1.6K
A Laminated Microfluidic Device for Comprehensive Preclinical Testing in the Drug ADME Process
Fan An1,2, Yueyang Qu1,2, Yong Luo1,2
1State Key Laboratory of Fine Chemicals, Department of Chemical Engineering, Dalian University of Technology, 2 Linggong Rd., Dalian 116024, China.
Scientific Reports
|April 29, 2016
Summary
A novel microfluidic device simulates drug absorption, distribution, metabolism, and excretion (ADME) testing, offering a faster, cost-effective alternative to traditional pre-clinical drug evaluation.
Area of Science:
- Biomedical Engineering
- Pharmacology
- Drug Discovery
Background:
- Conventional pre-clinical drug testing is lengthy and expensive.
- There is a critical need for innovative methods to streamline drug development.
- In vitro models are essential for predicting in vivo drug responses.
Purpose of the Study:
- To develop and validate a microfluidic device for comprehensive drug ADME testing.
- To create an in vitro system that mimics key physiological processes involved in drug disposition.
- To assess the utility of the device for evaluating drug efficacy and toxicity.
Main Methods:
- Fabrication of a multi-layered laminated microfluidic device.
- Culture of functional cells and organ tissues (Caco-2, hepatocytes, MCF-7, lung, heart, fat) within the device.
- Introduction of drugs to simulate absorption, metabolism, distribution, and elimination pathways.
- On-chip evaluation of drug anti-tumor activity, hepatotoxicity, and pharmacokinetics.
Main Results:
- The microfluidic device successfully mimicked in vivo drug ADME processes.
- The device demonstrated the ability to reflect hepatic drug metabolism and tissue distribution.
- Simultaneous evaluation of anti-tumor activity, hepatotoxicity, and pharmacokinetics was achieved.
- The system accurately modeled drug absorption, distribution, metabolism, and elimination.
Conclusions:
- The developed microfluidic device serves as a reliable tool for in vitro drug ADME assessment.
- This technology has the potential to significantly reduce drug candidate numbers and accelerate pre-clinical testing.
- The device offers a promising alternative to animal testing in early drug discovery phases.
